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EPIGENETIC STUDY AS A NEW APPROACH FOR THERAPEUTICS AND 
BIOMARKER OF ATHEROSCLEROSIS IN COVID-19 





Introduction : Coronavirus disease 2019 (COVID-19) has affected more than 105 million 
people globally and resulted in at least 2.3 million deaths. Covid-19 has highlighted the 
vulnerability of aging populations to emerging diseases. This susceptibility to disease and 
death is also a major challenge for the development of vaccines and immunotherapeutic 
agents. Atherosclerosis is one of the main cardiovascular disease, and this disease is one of 
the most common comorbid diseases affected by Covid-19 and is associated with 
increased risk of mortality. Biomarker are crucial in decision-making in order to facilitate 
efficient resource allocation. Recently many researcher develop several biomarker as a 
new approach in epigenetic area. The discovery of new therapeutic targets as well as 
biomarkers using epigenetic studies may increase its clinical usefulness.   
Methods: In this narrative review, a search was carried out with the help of several 
search engines that match the criteria, namely "Epigenetic Studies Based On 
Cardiovascular Disease Especially In Atherosclerosis".  
Results: One paper was obtained that supports and fits the criteria, namely the role of 
miRNA in the formation of atherosclerotic plaques.  
Conclusion: miR-486-5p can be used as a new therapeutic target and biomarker in 
atherosclerosis patients, but this requires further research. 
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INTRODUCTION 
Covid-19 disease first case was 
identified in Wuhan China on December 
2019. Covid-19 or previously known as 
2019 Novel Coronavirus (2019-nCoV) is 
the disease caused by an infection of the 
SARS-CoV-2 virus.1 April 6th 2021 on 
https://covid19.who.int, globally there 
have been 131.487.572 confirmed cases 
including 2.857.702 deaths reported to 
WHO. This virus spreads easily and very 
quickly, so that this viral infection is the 
cause of a global pandemic. Almost all 
countries in the world are hit by the 
Covid-19 disease and this has also caused 
significant deaths, economic losses and 
global panic. This virus is spread by 
contact with droplets of patients who are 
already infected with the corona virus 
when they cough or sneeze.1 
From the beginning of pandemic, 
heavy Covid-19 cases are attacked 
significantly more frequently elderly 
individuals and attendance of 
comorbidities. Elderly individuals and 
attendance of comorbidities had the 
highest death rate, even though Covid-19 
related deaths also reported on young or 
middle aged adults.2 Even based on cohort 
study Shi,. Shaobo, 2020, Cardiac injury is 
a general condition between hospitalized 
patients with COVID-19 in Wuhan, China, 
and it is associated with higher risk of in-
hospital mortality.3 The interaction among 
the spike (S) protein and angiotensin-
converting enzyme 2, which cause to the 
virus entry into host cells, possibility to be 
embroiled in the cardiovascular 
manifestations of COVID-19.4 
The most common comorbidities 
that are often diagnosed before elderly 
individuals infected with Covid-19 is 
hypertension, diabetes, stroke, dementia, 
COPD, chronic renal failure, and a lot of 
CVDs was significantly higher in older 
patients, such as atrial fibrillation, heart 
failure, stroke, hypertension and ischemic 
heart disease.(2,5) And some cardiovascular 
diseases can affect by a pathological 
condition in the form of atherosclerosis. 
Atherosclerosis is inflammatory process 
occurring as develop to accumulation of 
lipids within the arterial wall. It is a 
condition that must be handled properly so 
as not to cause dangerous symptoms.6 
Until now the Covid-19 pandemic 
is still happening and who knows when it 
will be over. This will have far-reaching 
and long-term effects on CVDs in elderly 
patients especially in the case of 
atherosclerotic plaque formation as a cause 
of various deadly heart diseases. 
Therefore, it needs tighter care for taking 
care of elderly during Covid-19 pandemic, 
one of them is by developing therapeutic 
therapy. Because Some medications used 
for the therapy of COVID-19 have rootless 
safety and efficacy profile, the clinicians 
need facing the problem this challenge by 
finding ways improve the ability of care 
delivery and improving the effectiveness 
and efficiency of CVDs therapy for elderly 
patient during the COVID-19 pandemic 
especially in determining new therapeutic 
targets and biomarkers in 
atherosclerosis.(4,7)  
Epigenetics research can expand 
antiviral drugs by evaluating specific 
epigenetic modulators as targets and 
exploring new chromatin-based therapies 
for different virus families (including 
coronaviruses), which can explain the 
interaction between the virus and the host. 
The basic new pattern of action and its 
role in disease severity.8  In the past few 
decades, a large number of studies have 
shown that epigenetics plays an important 
role in the conformation and progression 
of many common diseases (especially age-
related diseases).9 Further in patients with 
comorbidities, alteration undergone by the 
virus may be clear and quick. The changes 
of epigenetics can be important regulators 
that remodel host chromatin structure, 
gene expression patterns in a highly 
flexible mode. These changes can modify 
the cellular behavior including the host’s 
innate immune response.10  
  The correlation between epigenetics and 
cardiovascular disease, that is, 
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epigenetics is an emerging mechanism 
related to vascular biology and 
endothelial nutrition regulation. Through 
chromatin remodeling, epigenetics can 
modify endothelial function, thereby 
affecting cardiovascular diseases, because 
the regulatory function of epigenetics is 
also effective for endothelial precursor 
cells and circulating angiogenic 
cells.(11,12) DNA methylation, 
modification of histone, and the recently 
discovered mRNA mechanism represents 
an important pathway involved in 
epigenetic research For instance,  
vascular endothelial growth factor A 
(VEGF-A) and nitrite oxide synthase 
(NOS) are major chemical processes in 
maintaining and regulating 
cardiovascular functions. Epigenetic 
mechanisms are able to control their 
expression. Especially, VEGF A 
epigenetic control can expand mainly 
thru histone modification by RNAs. 
VEGF A serve by VEGFR2, which in 
modify is regulated according to 
promoter DNA methylation.12 
This narrative review to refer to 
explain research which describes new 
therapeutic targets and biomarkers in 
atherosclerosis based on epigenetic study 
which will used to atherosclerosis therapy 
as mainly comorbidities and major 
complication of Covid-19 infection. And 
we can taking care elderly during the 
pandemic furthermore. 
 
MATERIAL AND METHODS 
Search Methodology 
For the purpose of this narrative 
review, we used 4 search engine: PubMed, 
ScienceDirect, SpringerLink and Nature. 
The search criteria were restricted to article 
type based on level of evidence 
“Randomized Controlled Trial (RCT), 
Critically-appraised evidence, systematic 
review, and Meta-Analysis”. And the 
articles were published in English within 
the last three years, between March 2018 
until March 2021. We used three sets of 
keywords to encompass the eligible article  
“epigenetic study”, “elderly patients”, and 
“cardiovascular disease. The article were 
accessed, and relevant references were 
made for the aim of this review. 
This study focused on publications 
satisfying the following several conditions. 
Article have to implementation of 
epigenetics study to address CVDs in 
elderly patients, well it is DNA 
methylation, histone modifications or non-
coding RNA. Explain of reporting or 
discussing modification in studied patient 
outcomes or con editions. We excluded 
any research that did not report a estimated 
patient outcome, review or opinion article, 
and qualitative perception articles. After 
obtaining it, we will take a paper that 
refine search again on which reveals new 




Regarding the use of keywords, it 
was found 14 articles in PubMed, 498 
articles in SpringerLink, 186 articles in 
ScienceDirect, and 36 articles in nature 
(Figure 1).  
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Figure 1. PRISMA selection procedure 
Thus the total of articles have been 
founded were 734. We removed 637 
articles which do not match the criteria for 
the desired keywords using search 
engine’s filter. The authors screened the 
remaining 97 studies by reading abstracts 
and titles. Seventy six articles that did not 
meet our inclusion criteria were removed, 
and twenty one papers were shortlisted for 
full screening. The outcome of this process 
is one paper within the targeted scope and 
inclusion criteria. 
Journals that match the criteria, 
namely entitled “Regulation of 
microRNAs in coronary atherosclerotic 
plaque”. This paper describes research in 
that might be made as  new approach for 
therapeutics and biomarker of 
atherosclerosis. This study describes 
miRNA expression in patients with 
atherosclerosis.  They were collected 
coronary artery plaque (CAP) from 14 
coronary artery disease patients who 
underwent endarterectomy and bypass 
grafting caused by occlusive 
atherosclerosis. And Internal Mammary 
Arteries or IMA samples were used as 
control that acquired through bypass 
surgery. Analysis of histopathological  
conducted either on atherosclerotic or 
IMA tissues to confirm whether there is or 
not atherosclerosis. The miRNA profiles 
were compared using microarrays and 
quantitative PCR.13 
The result showed thirty-one 
differentially miRNAs expressed between 
CAP and IMA. And miR-486-5p showed a 
high level of regulation (12-fold), it has 
been predicted to interact with 
atherosclerosis-related genes, and is 
associated with triglyceride levels and 
arterial stenosis. The regulation of miR-
486-5p was verified by PCR (p = 0.004). 
miRNA is regulated in atherosclerotic 
plaques. The author focused on miR-486-







MicroRNA (miRNA) is a small non-
coding RNA that acts as a major player in 
post-transcriptional gene regulation in 
various species.14 According to reports, 
MicroRNA (miR) is involved in vascular 
inflammation and may represent a new type 
of diagnostic biomarker in cardiovascular 
disease. According to the study of 
Parahuleva et al., there are significant 
differences in miRNA expression profiles 
between atherosclerotic plaques and healthy 
control arteries. The most up-regulated 
miR, so-called atherosclerosis, is involved 
in cellular processes known to be involved 
in atherosclerosis. Using only a single 
molecule as a target, interference with 
miRNA expression in arteries is a potential 
means to affect plaque development in 
many ways. In the process of vascular 
wound healing, the interpretation of the 
complex cell and environment-specific 
effects of miRs seems to be crucial for the 
development of miRNA-based 
atherosclerosis therapy. In addition, the in 
vivo specific blockade of miR-21 and miR-
92a expression can reduce vascular 
inflammation and change the development 
of atherosclerosis, reduce plaque size and 
promote a more stable disease phenotype. 
MiR-21 and -92a may be new therapeutic 
targets for proliferative vascular diseases 
(such as atherosclerosis, restenosis after 
angioplasty, and graft vascular disease).15 
The correlation between miR-486-
5p and triglyceride levels suggests that this 
miRNA may play a role in the regulation of 
lipid metabolism. It has been previously 
demonstrated that the expression of miR-
486-5p is up-regulated in the serum of 
patients with coronary heart disease and can 
distinguish stable and fragile patients with 
coronary heart disease. Interestingly, the 
same study showed that miR-486-5p is 
related to HDL particles and is 
preferentially distributed in HDL subgroups 
HDL2 and HDL3. The elevated level of 
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miR-486-5p in HDL2 is especially related 
to the vulnerability of CAD patients.16 
Another study showed that 
inhibition of miR-486-5p by subcutaneous 
injection of antagomiRs into hyperlipidemia 
mice can reduce liver and plasma 
cholesterol.17 The prediction analyses 
suggested that miR-486-5p may target 
MAP3K7. This gene encodes for the 
serine/threonine kinase TAK1 which is a 
major upstream signaling molecule of TGF-
β1-induced type I collagen and fibronectin 
expression.(18,19) TAK1 is activated by TGF-
β1 and triggers the activation of several 
downstream signaling cascades such as NF-
κB-inducing kinase-IκB kinase.20 Which is 
activated in the endothelium of vascular 
regions susceptible to atherosclerotic 
injuries.(21,22) 
It has also been proposed that miR-
486 is related to cardiac hypertrophy, and 
the up-regulation of miR-486 helps to 
activate the Bcl-2 related mitochondrial 
apoptotic pathway, thereby exhibiting anti-
apoptotic function in cardiomyocytes.23 
According to these findings in experimental 
studies, miR-135a and miR-486 are 
considered to be opposite to the apoptosis 
pathway regulated by Bcl-2 in myocardial 
infarction remodeling. On the other hand, in 
several epidemiological studies, both miR-
135a and miR-486 in blood were positively 
correlated with IHD. Among Austrians, 
miR-135a and miR-486 in this study were 
significantly higher than those in Japan 
people.(24–26) 
Niculescu et al. determined the 
preferential distribution of miRNAs in HDL 
subgroups (HDL2, HDL3), which proved to 
be an important difference between the 
vulnerable CAD group and the stable CAD 
group. Therefore, we show here that the 
elevated levels of miR-486 in HDL2 and 
miR-92a in HDL3 are particularly related to 
the serum of vulnerable CAD patients (UA 
and MI groups). The mechanism for 
enhancing miRNA levels in HDL may 
involve the transfer of lipids to HDL cells 
and/or the activity of lipid transfer proteins 
that exchange lipids between apoB-
containing Lp and HDL. It is recognized 
that HDL carries miRNAs, but it is not yet 
known how they bind to HDL particles. 
Recent reports indicate that some miRNAs 
related to HDL act as communication 
messengers over long distances from the 
donor to the recipient cells, but the author 
cannot point out what tissue they originate 
from or whether they are involved in the 
regulation of HDL secretion.16 
The function of miRNA as a 
predicted to regulate genes known to be 
involved in the atherosclerosis pathway has 
been proven by several studies such as, 
which has been done by Ocal Berka et.all 
(2019) about Regulation of microRNAs in 
coronary atherosclerotic plaque by using a 
sample of 14 people who have 6 Coronary 
atherosclerosis plaque (CAP) and internal 
mammary arteries (IMAs). The present 
study allowed the identification of 
differentially expressed miRNAs between 
healthy vascular tissues (non- 
atherosclerotic plaques example IMA) and 
atherosclerosis tissue. The method used in 
this study was to compare microarrays and 
PCR analysis as it’s quantitative analysis. 
The results, they observed in microarray 
experiments that 31 miRNAs were not 
related to the atherosclerosis pathway and 
did not have a correlation between 
atherosclerotic and healthy tissues.13 
However, qPCR show a correlation with 
patient’s clinical data allowed the selection 
of miR-468-5p to be involved in the 
formation of atherosclerosis pathways. 
Because, miR-468 5p correlations with 
triglyceride levels suggests that this 
miRNA may have a role in the modulation 
of lipid metabolism.  
This is in accordance with the 
research conducted by Niculescu Loredan S 
et.all (2015) with the research title MiR-486 
and miR-92a Identified in Circulating HDL 
Discriminate between Stable and 
Vulnerable Coronary Artery Disease 
Patients. The investigation included 111 
subjects (38 women and 73 men, aged 24–
79 years with cardiovascular disease. 95 
patients with CAD (30 SA, 39 UA and 26 
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MI) and 16 healthy control subjects which 
show that expression of miR-486-5p has 
previously been shown to be upregulated in 
the sera of patients with CAD and was able 
to discriminate between stable and 
vulnerable CAD patients. interestingly, this 
study showed that miR-486-5p was 
associated with HDL particles, with a 
preferential distribution in the HDL 
subpopulations HDL2 and HDL3. Increased 
levels of miR-486-5p in HDL2 were 
particularly associated with vulnerability of 
CAD patients. Thus, high levels of miR-468 
circulating in the blood have the potential to 
be used as a biomarker in CAD. Mechanism 
that increase miRNA levels in HDL may 
involve cellular transfer of HDL lipids or 
due to the transfer activity of proteins 
containing ApoB and HDL.16 but only few 
succeeded in finding correlations between 
circulating miRNAs and other serum 
parameters already accepted as biomarkers 
for CAD.27 
Another study from Niculescu 
Loredan S et.all (2018) has identified the 
potential for reversal hyperlipidemia LNA 
miRNA inhibitor that is injected 
subcutaneously specifically for miR-468-
5p. Showed that the inhibition of miR-486-
5p by subcutaneous injection of 
antagomiRs to hyperlipidemic mice 
reduced hepatic and plasmatic cholesterol. 
LNA miRNA inhibitor was given for 2 
weeks and there was a significant 
reduction lipid levels in the liver and 
plasma of mice. Hyperlipidemia in mice 
plasma after being given an LNA miRNA 
inhibitor in decrease total cholesterol levels 
by 17,14% with a value of p= 0,4411. As 
expected, the treatment with miRNA 
inhibitors strongly reduced plasma levels 
of miR-486 (by 96%, p=0.0086), while in 
all control HL (hyperlipidemia) groups the 
miRNAs levels remained unchanged. They 
observed a similar effect in HL livers, the 
treatment with miRNA inhibitors strongly 
reduced the hepatic levels of miR-486 (by 
99.4%, p=2.45 × 10−7).17 They prediction 
analyses showed that miR-486-5p may 
target MAP3K7. This gene encodes for the 
serine/threonine kinase TAK1 which is a 
major upstream signaling molecule of 
TGF-β1-induced type I collagen and 
fibronectin expression. It’s known that 
when collagen type 1 and fibronectin are 
induced will cause the formation of 
atheroma plaques in atherosclerosis 
disease.(18,28) And the group of Liu et al. 
showed that miR-486 could indirectly 
inhibit ABCA1-mediated cholesterol 
efflux in THP-1 macrophages by direct 
targeting of histone acetyltransferase.29 
Niculescu Loredan S et.all (2018) 
reported that miRNA inhibitors, miR-486 
can directly regulate SOAT2 and SREBF1, 
which are two key enzymes involved in 
lipid metabolism. SOAT2 (or formerly 
ACAT2) is responsible for the formation 
of cholesteryl esters (CE) in the liver, 
preventing the accumulation of free 
cytotoxic cholesterol (FC).30 Therefore, the 
inhibitory effect of SOAT2 may lead to the 
cytotoxic accumulation of FC in 
hepatocytes, but it can also stimulate the 
excretion of FC into bile. They showed 
that a high-fat diet can induce a significant 
increase in liver and plasma miR-486 
levels, as well as an increase in liver 
weight, lipid accumulation and loss of 
SOAT2 gene expression in the liver of HL 
hamsters.31 This study proved that the 
restoration of SOAT2 expression by 
inhibiting miR-486 in vivo can reduce liver 




Micro RNA is branch of 
epigenetic study. Berkan et al, showed 
that miR-486-5p is highly potential as a 
new therapeutic target and biomarker in 
atherosclerosis patients, but this requires 
further research. 
ACKNOWLEDGEMENT 
Thank you to our teacher 
Khomaini Hasan, Ph.D, who has 
guided in the preparation of this 
narrative review. And our respect to 
our role model Arief Wibowo, MD, 
Online-ISSN 2565-1409  Journal of Widya Medika Junior Vol 3. No. 4 July 2021	
	
	 274 
Ph.D, who helped review this paper. 
Hopefully this paper can provide 
many benefits, especially in the 
development of atherosclerosis 
therapy. 
REFERENCES 
1.  Naser N, Masic I, Zildzic M. Public 
Health Aspects of COVID19 Infection 
with Focus on Cardiovascular 
Diseases. Mater Socio Medica. 
2020;32(1):71.  
2.  Palmieri L, Vanacore N, Donfrancesco 
C, Lo Noce C, Canevelli M, Punzo O, 
et al. Clinical Characteristics of 
Hospitalized Individuals Dying with 
COVID-19 by Age Group in Italy. 
Journals Gerontol - Ser A Biol Sci Med 
Sci. 2020;75(9):1796–800.  
3.  Shi S, Qin M, Shen B, Cai Y, Liu T, 
Yang F, et al. Association of Cardiac 
Injury with Mortality in Hospitalized 
Patients with COVID-19 in Wuhan, 
China. JAMA Cardiol. 2020;5(7):802–
10.  
4.  Nishiga M, Wang DW, Han Y, Lewis 
DB, Wu JC. COVID-19 and 
cardiovascular disease: from basic 
mechanisms to clinical perspectives. 
Nat Rev Cardiol [Internet]. 
2020;17(9):543–58. Available from: 
http://dx.doi.org/10.1038/s41569-020-
0413-9 
5.  Gerc V, Masic I, Salihefendic N, 
Zildzic M. Cardiovascular Diseases 
(CVDs) in COVID-19 Pandemic Era. 
Mater Socio Medica. 2020;32(2):158.  
6.  Grzegorowska O, Lorkowski J. 
Possible Correlations between 
Atherosclerosis, Acute Coronary 
Syndromes and COVID-19. J Clin 
Med. 2020;9(11):3746.  
7.  Lau D, McAlister FA. Implications of 
the COVID-19 Pandemic for 
Cardiovascular Disease and Risk-
Factor Management. Can J Cardiol. 
2020;  
8.  Atlante S, Mongelli A, Barbi V, 
Martelli F, Farsetti A, Gaetano C. The 
epigenetic implication in coronavirus 
infection and therapy. Clin Epigenetics 
[Internet]. 2020;12(1):1–12. Available 
from: https://doi.org/10.1186/s13148-
020-00946-x 
9.  Jin Z, Liu Y. DNA methylation in 
human diseases [Internet]. Vol. 5, 
Genes and Diseases. Chongqing 




10.  Schäfer A, Baric RS. Epigenetic 
landscape during coronavirus infection. 
Pathogens. 2017;6(1).  
11.  Yan MS, Marsden PA. Epigenetics 
in the Vascular Endothelium: Looking 
from a Different Perspective in the 
Epigenomics Era. Arterioscler Thromb 
Vasc Biol. 2015;35(11):2297–306.  
12.  Turunen MP, Ylä-Herttuala S. 
Epigenetic regulation of key vascular 
genes and growth factors. Cardiovasc 
Res. 2011;90(3):441–6.  
13.  Berkan Ö, Arslan S, Lalem T, 
Zhang L, Şahin NÖ, Aydemir EI, et al. 
Regulation of microRNAs in coronary 
atherosclerotic plaque. Epigenomics. 
2019;11(12):1387–97.  
14.  Suzuki HI, Miyazono K. Chapter 
Eight - Control of MicroRNA 
Maturation by p53 Tumor Suppressor 
and MCPIP1 Ribonuclease. In: Guo F, 
Tamanoi FBT-TE, editors. Eukaryotic 
RNases and their Partners in RNA 
Degradation and Biogenesis, Part B 
[Internet]. Academic Press; 2012. p. 
163–83. Available from: 
https://www.sciencedirect.com/science/
article/pii/B9780124047419000088 
15.  Parahuleva MS, Lipps C, Parviz B, 
Hölschermann H, Schieffer B, Schulz 
R, et al. MicroRNA expression profile 
of human advanced coronary 
atherosclerotic plaques. Sci Rep 
[Internet]. 2018;8(1):7823. Available 
from: https://doi.org/10.1038/s41598-
018-25690-4 
16.  Niculescu LS, Simionescu N, 
Sanda GM, Carnuta MG, Stancu CS, 
Popescu AC, et al. MiR-486 and miR-
 Epigenetic Study as new approach…  Ferdianti NF, Viradanti T, Utami SD	
	
	275 
92a identified in circulating HDL 
discriminate between stable and 
vulnerable coronary artery disease 
patients. PLoS One. 2015;10(10):1–13.  
17.  Niculescu LS, Simionescu N, Fuior 
E V., Stancu CS, Carnuta MG, 
Dulceanu MD, et al. Inhibition of miR-
486 and miR-92a decreases liver and 
plasma cholesterol levels by 
modulating lipid-related genes in 





18.  Hocevar BA, Prunier C, Howe PH. 
Disabled-2 (Dab2) mediates 
transforming growth factor β (TGFβ)-
stimulated fibronectin synthesis 
through TGFβ-activated kinase 1 and 
activation of the JNK pathway. J Biol 
Chem. 2005;280(27):25920–7.  
19.  Kim S Il, Kwak JH, Zachariah M, 
He Y, Wang L, Choi ME. TGF-beta-
activated kinase 1 and TAK1-binding 
protein 1 cooperate to mediate  TGF-
beta1-induced MKK3-p38 MAPK 
activation and stimulation of type I 
collagen. Am J Physiol Renal Physiol. 
2007 May;292(5):F1471-8.  
20.  Kim S Il, Choi ME. TGF-β-
activated kinase-1: New insights into 
the mechanism of TGF-β signaling and 





21.  Atkins GB, Simon DI. Interplay 
between NF-kB and kruppel-like 
factors in vascular inflammation and 
atherosclerosis: Location, location, 
location. J Am Heart Assoc. 
2013;2(3):2–4.  
22.  Jongstra-Bilen J, Haidari M, Zhu S-
N, Chen M, Guha D, Cybulsky MI. 
Low-grade chronic inflammation in 
regions of the normal mouse arterial 
intima  predisposed to atherosclerosis. 
J Exp Med. 2006 Sep;203(9):2073–83.  
23.  Sun Y, Su Q, Li L, Wang X, Lu Y, 
Liang J. MiR-486 regulates 
cardiomyocyte apoptosis by p53-
mediated BCL-2 associated 
mitochondrial apoptotic pathway. 
BMC Cardiovasc Disord [Internet]. 
2017;17(1):119. Available from: 
https://doi.org/10.1186/s12872-017-
0549-7 
24.  Hoekstra M, van der Lans CAC, 
Halvorsen B, Gullestad L, Kuiper J, 
Aukrust P, et al. The peripheral blood 
mononuclear cell microRNA signature 
of coronary artery disease. Biochem 
Biophys Res Commun. 2010 
Apr;394(3):792–7.  
25.  Zhang R, Lan C, Pei H, Duan G, 
Huang L, Li L. Expression of 
circulating miR-486 and miR-150 in 
patients with acute myocardial 
infarction. BMC Cardiovasc Disord 




26.  Niculescu LS, Simionescu N, 
Sanda GM, Carnuta MG, Stancu CS, 
Popescu AC, et al. MiR-486 and miR-
92a Identified in Circulating HDL 
Discriminate between Stable and 
Vulnerable Coronary Artery Disease 
Patients. PLoS One [Internet]. 2015 




27.  Creemers EE, Tijsen AJ, Pinto YM. 
Circulating MicroRNAs: Novel 
biomarkers and extracellular 
communicators in cardiovascular 
disease? Circ Res. 2012;110(3):483–
95.  
28.  Kim S Il, Kwak JH, Zachariah M, 
He Y, Wang L, Choi ME. TGF-β-
activated kinase 1 and TAK1-binding 
protein 1 cooperate to mediate TGF-
β1-induced MKK3-p38 MAPK 
activation and stimulation of type I 
collagen. Am J Physiol - Ren Physiol. 
2007;292(5):1471–9.  
Online-ISSN 2565-1409  Journal of Widya Medika Junior Vol 3. No. 4 July 2021	
	
	 276 
29.  Liu D, Zhang M, Xie W, Lan G, 
Cheng HP, Gong D, et al. MiR-486 
regulates cholesterol efflux by 
targeting HAT1. Biochem Biophys Res 
Commun [Internet]. 2016;472(3):418–
24. Available from: 
http://dx.doi.org/10.1016/j.bbrc.2015.1
1.128 
30.  Rogers MA, Liu J, Song BL, Li 
BL, Chang CCY, Chang TY. Acyl-
CoA:cholesterol acyltransferases 
(ACATs/SOATs): Enzymes with 
multiple sterols as substrates and as 
activators. J Steroid Biochem Mol Biol 




31.  Warrier M, Zhang J, Bura K, 
Kelley K, Wilson MD, Rudel LL, et al. 
Sterol O-Acyltransferase 2-Driven 
Cholesterol Esterification Opposes Liver X 
Receptor-Stimulated Fecal Neutral Sterol 
Loss. Lipids. 2016;51(2):151–7.  
 
 
